KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Non-Current Deffered Revenue (2019 - 2022)

Esperion Therapeutics (ESPR) has disclosed Non-Current Deffered Revenue for 3 consecutive years, with $211000.0 as the latest value for Q2 2022.

  • For the quarter ending Q2 2022, Non-Current Deffered Revenue fell 80.04% year-over-year to $211000.0, compared with a TTM value of $211000.0 through Jun 2022, down 80.04%, and an annual FY2021 reading of $634000.0, changed N/A over the prior year.
  • Non-Current Deffered Revenue was $211000.0 for Q2 2022 at Esperion Therapeutics, down from $422000.0 in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $1.1 million in Q2 2021 and bottomed at $211000.0 in Q2 2022.
  • Average Non-Current Deffered Revenue over 3 years is $637333.3, with a median of $644500.0 recorded in 2019.
  • Peak annual rise in Non-Current Deffered Revenue hit 80.04% in 2022, while the deepest fall reached 80.04% in 2022.
  • Year by year, Non-Current Deffered Revenue stood at $655000.0 in 2019, then fell by 3.21% to $634000.0 in 2021, then crashed by 66.72% to $211000.0 in 2022.
  • Business Quant data shows Non-Current Deffered Revenue for ESPR at $211000.0 in Q2 2022, $422000.0 in Q1 2022, and $634000.0 in Q4 2021.